Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)

Clinical Comprehensive Guide: Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)

1. Introduction and Overview

Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), also clinically categorized as Drug-Induced Hypersensitivity Syndrome (DIHS), represents one of the most severe and potentially life-threatening adverse drug reactions (ADRs). Unlike simple maculopapular exanthems, DRESS is a multisystem inflammatory process characterized by a delayed onset, prolonged clinical course, and the potential for long-term autoimmune sequelae.

The hallmark of DRESS is its paradoxical nature: it mimics infectious mononucleosis or lymphoma, often leading to diagnostic delays. With a mortality rate estimated between 5% and 10%, early recognition and immediate cessation of the offending agent are the primary determinants of clinical outcome.

2. Pathophysiology and Mechanisms

The pathophysiology of DRESS is complex, involving a delayed-type hypersensitivity reaction that integrates genetic predisposition, viral reactivation, and immune dysregulation.

The Triad of Mechanisms

1. Genetic Susceptibility: Specific Human Leukocyte Antigen (HLA) alleles have been linked to DRESS. For instance, HLA-B58:01 is strongly associated with Allopurinol-induced DRESS, while HLA-B15:02 is linked to Carbamazepine.
2. Drug Metabolism Defects: Deficiencies in detoxification enzymes (e.g., epoxide hydrolase) lead to the accumulation of reactive drug metabolites, which act as haptens, binding to proteins and triggering an immune response.
3. Viral Reactivation: The "Sequential Reactivation" theory suggests that drug exposure triggers the reactivation of latent herpesviruses, specifically Human Herpesvirus-6 (HHV-6), Epstein-Barr Virus (EBV), and Cytomegalovirus (CMV). This viral reactivation is thought to drive the systemic inflammatory cascade.

Immunologic Cascade

• T-cell Activation: Drug-specific CD8+ and CD4+ T-cells expand, migrating into the skin and visceral organs.
• Cytokine Storm: Elevated levels of IL-5, IL-10, and IFN-gamma contribute to eosinophilia and multi-organ inflammation.
• Regulatory T-cell (Treg) Impairment: Recent evidence suggests that a transient reduction in Treg function prevents the termination of the immune response, leading to the prolonged nature of DRESS.

3. Clinical Presentation and Staging

The RegiSCAR Scoring System

The RegiSCAR (European Registry of Severe Cutaneous Adverse Reactions) criteria are the clinical gold standard for diagnosis. A score of >5 indicates "Definite DRESS."

Clinical Stages

• Prodromal Phase (Days 1–2): Often presents with flu-like symptoms, fever, and pharyngitis.
• Acute Phase (Days 2–6 weeks): Development of morbilliform rash, facial edema (a clinical hallmark), and systemic organ involvement.
• Recovery Phase (Weeks to Months): Gradual resolution of rash, but potential for flare-ups if corticosteroids are tapered too rapidly.

4. Differential Diagnosis

Because DRESS mimics several other conditions, clinicians must maintain a high index of suspicion.

5. Diagnostic Testing Protocols

Management requires a rigorous laboratory workup to assess the extent of end-organ damage.

Essential Laboratory Tests

1. Complete Blood Count (CBC): Monitor for eosinophilia and atypical lymphocytes.
2. Liver Function Tests (LFTs): ALT/AST elevation is common; monitor for hepatitis.
3. Renal Function: Serum creatinine and BUN; assess for acute interstitial nephritis.
4. Viral PCRs: HHV-6, EBV, and CMV PCR monitoring.
5. Cardiac Markers: Troponin and BNP if myocarditis is suspected.

6. Risks, Side Effects, and Long-Term Prognosis

High-Risk Medications (The "DRESS-Inducers")

• Anticonvulsants: Carbamazepine, Phenytoin, Lamotrigine, Phenobarbital.
• Antibiotics: Sulfonamides, Vancomycin, Minocycline.
• Urate-lowering agents: Allopurinol.
• Antivirals: Nevirapine, Abacavir.

Long-Term Sequelae

Patients are at risk of developing autoimmune disorders following the resolution of DRESS, including:
* Type 1 Diabetes Mellitus.
* Autoimmune Thyroiditis.
* Systemic Lupus Erythematosus (SLE).
* Chronic Hepatitis.

7. Management Strategy

1. Immediate Cessation: Stop all non-essential medications immediately.
2. Supportive Care: Fluid management, electrolyte replacement, and wound care for skin rash.
3. Systemic Corticosteroids: The cornerstone of treatment. High-dose (Prednisone 0.5–1.0 mg/kg/day) is typically required.
4. Tapering: Must be done slowly (over 6–8 weeks) to prevent rebound phenomena.
5. Second-line therapy: In steroid-refractory cases, IVIG, Cyclosporine, or Mycophenolate Mofetil may be considered.

8. Frequently Asked Questions (FAQ)

Q1: How long after starting a drug does DRESS typically appear?
A: Unlike other drug rashes that appear within days, DRESS has a long latency period, typically 2 to 8 weeks after initial drug exposure.

Q2: Is facial edema a sign of DRESS?
A: Yes, facial edema is a highly specific clinical sign of DRESS and is present in approximately 75% of cases.

Q3: Can DRESS recur?
A: Yes. If the patient is re-exposed to the offending drug or a structurally similar agent, the reaction can recur with even greater severity.

Q4: Is it safe to use corticosteroids for all DRESS patients?
A: Systemic corticosteroids are the gold standard, but they must be used cautiously in patients with severe underlying infections (e.g., uncontrolled viral reactivation).

Q5: What is the most common organ involved in DRESS?
A: The liver is the most frequently involved organ, ranging from mild transaminitis to fulminant hepatitis.

Q6: Why is viral reactivation significant?
A: Viral reactivation (especially HHV-6) correlates with more severe organ involvement and a more prolonged clinical course.

Q7: Can I switch to a different drug in the same class?
A: Cross-reactivity is common within drug classes (e.g., aromatic anticonvulsants). It is generally advised to avoid the entire class.

Q8: How long does the recovery process take?
A: The recovery phase is notoriously slow, often taking several weeks to months. Rapid tapering of steroids often leads to clinical relapse.

Q9: Is skin biopsy necessary for diagnosis?
A: A biopsy can help rule out other conditions like lymphoma or SJS, but it is not diagnostic for DRESS alone.

Q10: Are there long-term risks after the rash resolves?
A: Yes. Patients are at an increased risk of developing autoimmune conditions like thyroiditis or diabetes for months or years after the initial episode.

9. Conclusion

DRESS is a clinical diagnosis that requires a high index of suspicion. Given its systemic nature and potential for long-term morbidity, clinicians must prioritize early drug withdrawal and multi-disciplinary monitoring. By understanding the underlying immunologic mechanisms and strictly adhering to the RegiSCAR scoring guidelines, medical professionals can effectively manage this complex syndrome and improve patient survival rates.

Disclaimer: This guide is for educational purposes for healthcare professionals and does not constitute individual medical advice. Always consult current clinical guidelines and institutional protocols when managing severe drug hypersensitivity reactions.